Equillium
(NASDAQ:EQ)
$2.11
0.07[3.43%]
At close: Jul 1
$2.10
-0.0100[-0.47%]
After Hours: 9:25AM EDT
Day High/Low2.03 - 2.16
52 Week High/Low1.66 - 7.12
Open / Close2.08 / 2.11
Float / Outstanding17.1M / 34.3M
Vol / Avg.39.5K / 30.7K
Mkt Cap72.3M
P/E-
50d Avg. Price2.33
Div / Yield-
Payout Ratio-
EPS-1.17
Total Float17.1M

Equillium (NASDAQ:EQ), Quotes and News Summary

Equillium (NASDAQ: EQ)

Day High/Low2.03 - 2.16
52 Week High/Low1.66 - 7.12
Open / Close2.08 / 2.11
Float / Outstanding17.1M / 34.3M
Vol / Avg.39.5K / 30.7K
Mkt Cap72.3M
P/E-
50d Avg. Price2.33
Div / Yield-
Payout Ratio-
EPS-1.17
Total Float17.1M
Benzinga - Jun 21, 2022, 4:44AM
Benzinga - May 12, 2022, 4:17PM
Benzinga - Mar 23, 2022, 4:02PM
Benzinga - Dec 13, 2021, 8:04AM
Benzinga - Nov 10, 2021, 4:06PM
load more
Sector: Health Care.Industry: Biotechnology
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-09
REV
Q1 2022Est.ActualSurprise
EPS-0.370-0.450 -0.0800
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Equillium Questions & Answers

Q
How do I buy Equillium (EQ) stock?
A

You can purchase shares of Equillium (NASDAQ: EQ) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Equillium's (EQ) competitors?
Q
What is the target price for Equillium (EQ) stock?
A

The latest price target for Equillium (NASDAQ: EQ) was reported by HC Wainwright & Co. on Thursday, March 24, 2022. The analyst firm set a price target for 15.00 expecting EQ to rise to within 12 months (a possible 610.90% upside). 3 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Equillium (EQ)?
A

The stock price for Equillium (NASDAQ: EQ) is $2.11 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Equillium (EQ) pay a dividend?
A

There are no upcoming dividends for Equillium.

Q
When is Equillium (NASDAQ:EQ) reporting earnings?
A

Equillium’s Q2 earnings are confirmed for Tuesday, August 9, 2022.

Q
Is Equillium (EQ) going to split?
A

There is no upcoming split for Equillium.

Q
What sector and industry does Equillium (EQ) operate in?
A

Equillium is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.